Evaluación de la formulación magistral como paliativo en pacientes en la Unidad Oncológica SOLCA Chimborazo,

Abstract

The objective of the research was to evaluate the master formula as a palliative in patients in the Oncology Unit SOLCA CHIMBORAZO and based on the results propose a model to the pharmaceutical service through a practical guide where guidelines are established that link to the master formulation as a palliative tool for oncological patients. The study samples consisted of: 30 oncology patients and 20 health professionals (specialist physicians, nursing staff and pharmaceutical biochemist). The information was obtained through bibliographical sources, interviews with the representative of the pharmaceutical service (pharmaceutical biochemist), surveys carried out both oncological patients and different health professionals. Subsequently, the statistical analysis was performed using Excel and SPSS. The results of the research showed that 73.33% of cancer patients had breast cancer of which 18.6% said they had alopecia (hair loss) as the most prevalent side effect. It is concluded that breast cancer is the pathology that prevails in ages between 60 and 64 years and the side effect of greater incidence was alopecia manifested by both oncological patients and health personnel. It is recommended to give greater strength to the pharmaceutical services of the Oncology Centers of the country in order to be an active part in the palliative therapies for this type of patients that is increasing every day.